Y Dündar

University of Liverpool — United Kingdom

Medicine · Health Sciences

39h-index4.3kcitations203works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(23), Health Systems, Economic Evaluations, Quality of Life(14), Coronary Interventions and Diagnostics(12), Lung Cancer Diagnosis and Treatment(12), Acute Myocardial Infarction Research(7)

Publications203 total

Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
PharmacoEconomics - Open·2023Open Access
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
PharmacoEconomics - Open·2023· 9 citedOpen Access
Urinary Tract Infections: Test or Treat and How to Treat?
2023
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2023· 1 citedOpen Access
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2023· 2 citedOpen Access
Review for "Association of pharmacological treatments and real‐world outcomes in borderline personality disorder"
2023
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
Cochrane Database of Systematic Reviews·2021· 73 citedOpen Access
Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Cochrane Database of Systematic Reviews·2020· 45 cited
Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2020· 6 citedOpen Access
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2020· 3 citedOpen Access
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
Health Technology Assessment·2020· 38 citedOpen Access
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
BMC Cancer·2019· 46 citedOpen Access
Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2019· 25 citedOpen Access
Heated Humidified High-Flow Nasal Cannula for Preterm Infants: An Updated Systematic Review and Meta-analysis
International Journal of Technology Assessment in Health Care·2019· 34 cited
Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Cochrane Database of Systematic Reviews·2018· 53 citedOpen Access
A systematic review of the diagnostic accuracy of automated tests for cognitive impairment
International Journal of Geriatric Psychiatry·2018· 50 citedOpen Access
Measures for assessing an index test against a reference standard
2016
Studies excluded, with reasons
2016
Names of all of the tests identified
2016
Organisations approached for service user involvement
2016
page 1 of 11Next →

Frequent Co-authors

Angela Boland(30), Rumona Dickson(30), A Bagust(22), J Greenhalgh(18), Nigel Fleeman(16), T Walley(13), C McLeod(11), J Oyee(8), C Proudlove(8), Kerry Dwan(7), Marty Richardson(6), Ruaraidh Hill(5), Jo Hockenhull(5), Sophie Beale(5), Rubén Mújica-Mota(4), Juliet Hockenhull(4), Mary Gemma Cherry(4), C Martin Saborido(4), Susanna Dodd(3), Alan Haycox(3)